Summary of how the Tx paradigm for HF has changed.

27 August 2021 (15:05 - 15:10)

Organised by:

About the speaker

Professor Biykem Bozkurt

Baylor College of Medicine, Houston (United States of America)

5 More presentations in this session

Presentation thumbnail

SGLT-2 Inhibitors in Heart Failure: Where are we now and where are we heading?

Professor A. Stewart Coats (Sydney, AU)

Presentation thumbnail

Unanswered Questions.

Professor A. Stewart Coats (Sydney, AU) Professor B. Bozkurt (Houston, US) Professor C. Lam (Singapore, SG)

Presentation thumbnail

Best practice of SGLT-2 inhibitors in HFrEF: What constitutes best practice today?

Professor C. Lam (Singapore, SG)

Presentation thumbnail

Implementation in Practice: What are the Practical Considerations?

Professor A. Stewart Coats (Sydney, AU) Professor C. Lam (Singapore, SG) Professor B. Bozkurt (Houston, US)

Presentation thumbnail

Q&A.

Professor A. Stewart Coats (Sydney, AU) Professor B. Bozkurt (Houston, US) Professor C. Lam (Singapore, SG)

Access the full session

Session thumbnail

A Changing Paradigm: Defining the Future Role of SGLT-2 Inhibitors

The Event

ESC Congress 2021 - The Digital Experience

27 August 2021 15:05 CET

You may be interested in

Congress Presentation

Welcome and opening remarks

11 May 2026

Congress Session

What roles do we play in transforming the NHS? Industry partnerships and allied professionals driving innovative models of care

23 June 2023

Congress Session

Advances in medical therapy in heart failure

20 May 2025

Congress Session

Solving the puzzle of heart failure treatment

18 May 2025

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources